ArticleBone marrow transplantation2017

Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.

D Modi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.